Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives.

A clear trend toward decreasing hazard ratio of death with increasing TMB cut-off was observed across cancer types demonstrating increasing benefit from ICI with higher TMB.

also in 17,366 other papers

The median OS was 13.9 months with nivolumab plus ipilimumab versus 13.5 months with EXTREME in the all randomly assigned population (HR = 0.95; CI, 0.80 to 1.13; p = 0.4951); it was 17.6 months versus 14.6 months in the CPS ≥ 20 population (HR = 0.78; CI, 0.59 to 1.03; p = 0.0469) and did not reach statistical significance in either two primary endpoints.

also in 98,063 other papers

The ORR was 43% (95% CI, 32 to 54), and the median OS showed a positive trend with 12.1 months ( NCT04489888 ).

also in 9,721 other papers